High-Risk Breast Cancer Patients May Not Need a Mastectomy

Article

An abstract presented at the 13th Annual Meeting of the American Society of Breast Surgeons suggests that women who are at high risk for recurrence may not need a mastectomy.

An abstract presented at the 13th Annual Meeting of the American Society of Breast Surgeons, “Biology, Not Choice of Mastectomy versus Lumpectomy, Dictates Recurrence in High-Risk Breast Cancer,” suggests that women who are at high risk for breast cancer recurrence may not need a mastectomy. The data was presented by Elizabeth Cureton, MD, the University of California in San Francisco. The study asked whether breast conservation for high-risk women is safe.

Surgeons perform a mastectomy on a patient

As part of the I-SPY prospective neoadjuvant trial, patients who had had either a mastectomy or lumpectomy were followed for a median of 3.9 years. Follow-up care included serial MRIs and molecular profiling analyses. Nine clinical centers participated in the trial.

All patients had invasive breast cancer with tumors greater than 3 cms. Overall, local recurrence was low. Of 157 patients, 35 had distant recurrence with no signs of local recurrence; 10 patient had distal recurrence, either synchronous with local recurrence or within 2 years of local recurrence.

The 4-year trial classified patients as high risk based on factors such as tumor size, node status, and genetic markers. These factors dictated choice between mastectomy and lumpectomy. All patients underwent aggressive neoadjuvant chemotherapy in addition to surgery.

Patients with local recurrence alone were rare-only four patients had local recurrence with no distal recurrence. This observation led to the hypothesis that aggressive tumor biology underlies distal recurrence, irrespective of surgery type.

Analysis of patients in the I-SPY 1 registry confirmed that treatment type could not predict rates of recurrence. The 5-year survival of patients who had either a lumpectomy or a mastectomy were almost the same-79% vs 72%, respectively (P = .22).

Dr. Cureton and her team concluded that local and distal recurrence is affected by aggressive biology and response to treatment, and not by surgery type. They also suggest that if radiation therapy is suggested, breast conservation should be attempted. Breast conservation surgery generally leads to less potential for surgical complications, and the surgery is safe for higher risk patient populations, particularly when patients also receive radiation therapy as part of their treatment.

Further studies should help clarify whether mastectomy rates could be drastically decreased without sacrificing patient outcomes.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.